Sandoz, a division of Swiss pharma giant Novartis, has agreed to acquire GSK’s cephalosporin antibiotics business in a deal worth up to $500 million. The deal gives Sandoz global rights to the Zinnat, Zinacef, and Fortum brands in over 100 markets. However, the deal does not include the rights in the US, Australia, and Germany […]